Setara Biosciences
Developing genetically informed precision medicines for severe rare diseases.
Website: https://www.setarabiosciences.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Setara Biosciences |
| Tagline | Developing genetically informed precision medicines for severe rare diseases. [Business Wire, October 2026] |
| Headquarters | San Diego, CA [Business Wire, October 2026] |
| Founded | 2026 [Business Wire, October 2026] |
| Stage | Series A [Business Wire, October 2026] |
| Business Model | Other |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Growth Profile | Venture Scale |
| Founding Team | Corporate Spinout [Business Wire, October 2026] |
| Funding Label | $50M+ |
| Total Disclosed Funding | $90,000,000 [Business Wire, October 2026] |
Links
Open sources
- Website: https://www.setarabiosciences.com/
What an Investor Needs First
PUBLIC Setara Biosciences is a newly launched clinical-stage biotech focused on genetically informed precision medicines for severe rare diseases, and it merits investor attention now because it came to market with a $90 million Series A and a lead asset already carrying forward from the Actio Biosciences platform [Business Wire, October 2026] [Fierce Biotech, October 2026] [BioPharma Dive, October 2026]. The founding story is unusually specific: Setara was formed as a spinout following Jazz Pharmaceuticals' acquisition of Actio Biosciences, with the remaining Actio pipeline transferred into a new company rather than left behind as non-core inventory [Business Wire, October 2026] [Fierce Biotech, October 2026].
The core program is STAR-0871, described as an oral small-molecule TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C and overactive bladder, which gives Setara a clearer starting point than most newly formed rare-disease companies because the asset had already completed the healthy-volunteer portion of a Phase 1 trial initiated by Actio in March 2025 [Setara Biosciences] [Pharmacally] [Fierce Biotech, October 2026]. The differentiation case rests less on platform breadth than on asset provenance and target selection: Setara is positioning itself around human genetics and inherited disease biology, then extending from a clinical-stage program into earlier work in rare disease and adjacent neurology indications [Business Wire, October 2026] [BioPharma Dive, October 2026] [Axios Pro, October 2026].
Leadership continuity is another part of the underwriting case. David Goldstein, identified in launch coverage as president and executive chair and independently documented as Actio's founder and a Columbia genetics professor, brings domain credibility in human genetics, while David Breckenridge and Cayce Denton appear to have moved over from Actio into the CSO and CFO seats, respectively [Business Wire, October 2026] [Bloomberg Markets] [Reuters, April 2016] [LinkedIn].
The financing syndicate is strong on paper, with Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures, and Jazz Pharmaceuticals all named in the October 2026 Series A announcement [Business Wire, October 2026] [Axios Pro, October 2026]. For now, the business model is still a development-stage biotech model rather than a commercial one, so the near-term questions are clinical execution, regulatory progress, and whether the company can convert inherited program momentum into new proof points under the Setara name [BioPharma Dive, October 2026] [GenomeWeb, October 2026].
Over the next 12 to 18 months, the main public milestones to watch are whether STAR-0871 advances into the planned Phase 1b CMT2C study in 2027 and whether management adds sharper disclosure around the earlier pipeline beyond broad references to rare diseases, epilepsy, and migraine [Fierce Biotech, October 2026] [BioPharma Dive, October 2026] [Business Wire, October 2026]. The company starts with meaningful capitalization and a credible scientific lineage, but investors will still need fresh, Setara-specific data before the launch narrative matures into a differentiated clinical thesis [Fierce Biotech, October 2026] [GenomeWeb, October 2026].
Partially corroborated -- Core financing and spinout facts are corroborated by multiple public sources, but several leadership and pipeline details rely on company materials or single-source public reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Other |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Growth Profile | Venture Scale |
| Founding Team | Corporate Spinout |
| Funding | $50M+ total disclosed, approximately $90,000,000 [Business Wire, October 2026] |
Inside the Company
PUBLIC
Setara Biosciences came to market with an unusually clear origin story. The company says it was formed as a spinout of Actio Biosciences following Jazz Pharmaceuticals’ acquisition of Actio, and it positions itself around translating genetic insights into precision medicines for severe rare diseases [Setara Biosciences, retrieved 2026]. The company is headquartered in San Diego, California, according to the structured company facts provided for this report [Setara Biosciences, retrieved 2026].
The first disclosed milestone is the company’s public launch on October 30, 2026, alongside a $90 million Series A financing [Business Wire, October 2026]. In the same announcement, Setara said the financing would support development of its pipeline and identified a syndicate that included Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures, and Jazz Pharmaceuticals [Business Wire, October 2026].
Public materials also frame Setara as the continuation vehicle for programs that remained outside Jazz’s acquisition focus. The company website states that Setara was formed after the Jazz-Actio transaction and is building on Actio’s scientific foundation, while the launch announcement describes a strategy centered on genetically informed precision medicines for rare genetic diseases [Setara Biosciences, retrieved 2026] [Business Wire, October 2026].
Claim stands unchecked -- This section relies primarily on company website and company announcement materials, with no corroborating state filing or Crunchbase source provided in the structured research.
Under the Hood
MIXED
Setara is entering the public market with a single clearly identified technical story: a genetics-led rare disease platform anchored by one clinical-stage asset, rather than a broad disclosed toolkit or software stack [Business Wire, October 2026] [Setara Biosciences]. The company says it develops small-molecule precision medicines informed by human genetics and that it was formed from Actio Biosciences programs retained after Jazz Pharmaceuticals acquired Actio [Setara Biosciences] [Business Wire, October 2026]. Public materials point to STAR-0871 as the lead program, described as an oral small-molecule TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C and overactive bladder [Setara Biosciences] [Fierce Biotech, October 2026] [Pharmacally].
The product evidence is stronger on asset identity than on mechanism depth or platform detail. Coverage from Fierce Biotech reports that the healthy-volunteer portion of a Phase 1 trial, begun under Actio in March 2025, had been completed by Setara's October 2026 launch, and the same reporting says the program had received FDA rare pediatric disease, orphan drug, and fast-track designations [Fierce Biotech, October 2026]. Business Wire and the company website also frame Setara's approach as translating genetic insights into precision medicines for severe rare diseases, while third-party coverage links STAR-0871 to the former Actio asset ABS-0871, which helps establish continuity between the pre-spinout and post-spinout program narrative [Business Wire, October 2026] [Setara Biosciences] [allsci.com].
What remains less developed in the public record is the underlying discovery engine beyond that top-line genetics claim. The website references expertise in Mendelian genetics, drug discovery, and data science, and press coverage says the company intends to pursue additional earlier-stage programs in rare diseases and related indications, but the public materials reviewed do not establish assay design, translational workflow, biomarker strategy, or any differentiated computational infrastructure [Setara Biosciences] [Business Wire, October 2026] [BioPharma Dive, October 2026]. For now, the technical case rests on whether a genetically informed target-selection process can translate into clinically meaningful readouts in a narrow, severe indication where standard development paths are often difficult but scientifically interpretable.
Partially corroborated -- Core product identity is corroborated by the company website, Business Wire, and third-party trade coverage, but several development details remain supported by a limited set of public reports.
Market Research
PUBLIC
The market matters now because Setara is entering a part of biotech where regulatory incentives, genetics-led target selection, and orphan-disease capital formation have stayed active even as broader drug development funding has become more selective [Fierce Biotech, October 2026] [Business Wire, October 2026].
Public sources do not provide a cited TAM, SAM, or SOM for Setara’s initial indications, so the cleaner way to frame demand is through the market structure the company is actually stepping into. Setara’s lead asset, STAR-0871, is being developed for Charcot-Marie-Tooth disease type 2C and overactive bladder, with the company also describing earlier-stage work in rare diseases, epilepsy, and migraine [Setara Biosciences, retrieved 2026] [Pharmacally, retrieved 2026] [BioPharma Dive, October 2026]. That makes this less a single-indication story than a platform bet on ion-channel and genetically anchored neurology programs, with one ultra-rare use case and one broader expansion indication already named in public materials [Business Wire, October 2026] [Fierce Biotech, October 2026].
The immediate demand signal is not volume, it is unmet need. Coverage from Fierce Biotech and BioPharma Dive positions STAR-0871 around CMT2C, a rare inherited neuropathy, where small patient populations can still support development if the biology is clear and the regulatory path is workable [Fierce Biotech, October 2026] [BioPharma Dive, October 2026]. The same sources also note overactive bladder as a second indication, which broadens the commercial logic if proof of mechanism translates beyond the rare-disease entry point [Fierce Biotech, October 2026] [BioSpace, October 2026].
Regulatory tailwinds are more concrete than market-sizing data in the public record. Fierce Biotech reported that Setara’s lead program has received FDA rare pediatric disease, orphan drug, and fast-track designations, a combination that can shorten timelines, improve investor tolerance for narrow first launches, and support pricing power if efficacy emerges in a genetically defined population [Fierce Biotech, October 2026]. The company’s October 2026 financing, announced at $90 million, also suggests that specialist biotech investors still view rare genetic disease as a financeable category when there is a clinical-stage asset and a prior-company provenance behind it [Business Wire, October 2026] [Axios Pro, October 2026].
Adjacent markets matter because they shape the ceiling on any one asset. Setara’s own framing points to expansion indications in neurology and urology, while public coverage also mentions earlier-stage interests in epilepsy and migraine, both of which are much larger research and commercial arenas than a single Mendelian neuropathy program [Business Wire, October 2026] [BioPharma Dive, October 2026]. The central question for investors is whether TRPV4 inhibition proves to be a narrow orphan strategy or a biology with repeatability across better-capitalized adjacent categories.
| Public market framing | What the sources support |
|---|---|
| Rare genetic disease entry point | STAR-0871 is being developed for CMT2C, a severe inherited neuropathy [Fierce Biotech, October 2026] [BioPharma Dive, October 2026] |
| Broader adjacent market | Public sources also name overactive bladder as an indication for STAR-0871 [Pharmacally, retrieved 2026] [BioSpace, October 2026] |
| Pipeline adjacency | Earlier-stage programs are described in rare diseases, epilepsy, and migraine [Business Wire, October 2026] [Axios Pro, October 2026] |
| Regulatory support | FDA rare pediatric disease, orphan drug, and fast-track designations were reported for the lead program [Fierce Biotech, October 2026] |
The public evidence points to a company choosing a rare-disease beachhead with optionality into larger adjacent markets, rather than trying to prosecute a mass-market thesis from day one. What is still missing from the public record is the third-party market sizing that would let investors translate that strategy into a disciplined revenue envelope.
Partially corroborated -- This section relies on named public reporting and company materials, but it lacks independent third-party market size studies for TAM, SAM, or SOM.
Competition and Substitutes
MIXED Setara enters the field less as a broad rare-disease platform competing on scale, and more as a narrowly defined ion-channel and human-genetics bet built around a single inherited clinical asset, which means its real alternatives are incumbent neurologic and rare-disease drug developers, the residual Actio storyline now inside Jazz, and adjacent small-biotech programs pursuing genetically stratified patients through different target classes [Business Wire, October 2026] [Fierce Biotech, October 2026] [BioPharma Dive, October 2026].
The competitive map is clearest if broken into segments rather than named peers, because the available public reporting does not identify direct company-by-company rivals for TRPV4-related disease. In the inherited-asset segment, Setara is effectively competing with the post-acquisition baseline created by Jazz Pharmaceuticals, which bought Actio for $820 million around ABS-1230 while Setara carried forward the remaining pipeline, including ABS-0871, now STAR-0871 [Fierce Biotech, October 2026]. In the broader rare-disease neurology segment, the substitutes are larger companies with existing specialist-commercial footprints and trial infrastructure, while in adjacent precision-medicine biotech Setara sits among newer companies trying to use genetics to select targets before clinical proof has fully arrived [Business Wire, October 2026] [GenomeWeb, October 2026]. The practical implication is that Setara is not yet defending share in a commercial market, it is competing for something earlier: investigator attention, patient identification, and investor belief that this retained asset deserves to outrun both internal big-pharma priorities and other venture-backed rare-disease programs [BioPharma Dive, October 2026] [Axios Pro, October 2026].
Setara does have a visible edge today, though it is concentrated rather than broad. The first advantage is asset maturity: public coverage says STAR-0871 had completed the healthy-volunteer portion of a Phase 1 trial begun by Actio in March 2025, which places the company ahead of a purely preclinical rare-disease startup on timing [Fierce Biotech, October 2026]. The second is team continuity, with David Goldstein linked publicly to both Actio and Setara, and David Breckenridge and Cayce Denton also described as Actio alumni, which matters because spinouts often lose program memory during asset transfers [Bloomberg Markets] [BioPharma Dive, October 2026] [LinkedIn] [Business Wire, October 2026]. The third is regulatory positioning: Fierce Biotech reported rare pediatric disease, orphan drug, and fast-track designations for the lead program, which can sharpen trial design discussions and future partner interest even if they do not establish efficacy [Fierce Biotech, October 2026]. That edge is durable only if Setara can convert inherited context into new data. Team continuity and designations help early, but they fade quickly if the 2027 Phase 1b plan slips or produces equivocal signal [BioPharma Dive, October 2026].
The company is most exposed where larger organizations have structural advantages that capital alone does not erase. Jazz is the clearest named comparator in that sense, not because it appears to be a direct head-to-head competitor on STAR-0871, but because the origin story itself highlights what Setara does not control: a scaled balance sheet, established development infrastructure, and the option value to prioritize a different asset if the category shifts [Fierce Biotech, October 2026]. Setara also does not appear, from the public record reviewed, to own a differentiated distribution channel, a disclosed patient-finding network, or named external partnerships that would create barriers to entry around rare-disease recruitment [Business Wire, October 2026] [BioPharma Dive, October 2026]. In practical terms, that leaves the company dependent on execution in a narrow indication where specialist relationships and genotype-defined patient discovery can become the real bottleneck, especially for a newly launched biotech without a disclosed commercial infrastructure [GenomeWeb, October 2026].
The most plausible 18-month competitive scenario is still data-led rather than market-led. Winner if X: Setara, if the planned Phase 1b CMT2C study starts on time and shows a clean enough signal to validate TRPV4 inhibition in a genetically defined neuromuscular population, because few public challengers are yet attached to that exact narrative and the company would move from spinout story to clinical readout story [BioPharma Dive, October 2026] [Fierce Biotech, October 2026]. Loser if Y: Jazz, if the strategic logic of separating non-core Actio assets into Setara ends up looking conservative and STAR-0871 appreciates materially outside the acquired platform, since that would highlight foregone upside rather than retained focus [Fierce Biotech, October 2026]. The inverse also holds. If the study timeline stretches or signal quality disappoints, larger rare-disease incumbents and diversified neurologic developers remain advantaged simply because they can absorb delay more easily than a company whose public competitive case is centered on one lead program and a fresh $90 million financing [Business Wire, October 2026] [Axios Pro, October 2026].
Partially corroborated -- This section relies on named-publisher reporting from Business Wire, Fierce Biotech, BioPharma Dive, GenomeWeb, Axios Pro, Bloomberg Markets, and LinkedIn, but the public source set does not name direct competitors for a company-by-company comparison, so parts of the competitive map are analytical inferences from disclosed positioning and asset history.
Opportunity
PUBLIC
The prize here is not a broad rare-disease platform in the abstract, but a chance to turn a post-spinout clinical asset into a repeatable genetics-led company with multiple shots on goal, starting from a program that is already in human testing rather than on a discovery bench [Business Wire, October 2026] [Fierce Biotech, October 2026].
Setara's headline opportunity is to become a durable rare-disease precision-medicine company built around genetically validated ion-channel biology, with STAR-0871 as the proof point that makes the rest of the platform credible [Business Wire, October 2026] [GenomeWeb, October 2026]. That is reachable, not merely aspirational, because the company did not launch with a preclinical concept. It launched with $90 million in Series A financing, a lead oral small-molecule TRPV4 inhibitor, and a leadership team carried over from Actio after Jazz Pharmaceuticals acquired Actio and left the remaining pipeline to the spinout [Business Wire, October 2026] [BioPharma Dive, October 2026] [Fierce Biotech, October 2026]. The starting position matters. In biotech, a company that begins life with a clinical-stage asset, specialist investors, and a strategic shareholder has already cleared several of the usual formation risks.
The upside case still depends on execution in a narrow disease area first. But the evidence base supports a specific path: STAR-0871 is being developed for Charcot-Marie-Tooth disease type 2C and overactive bladder, the healthy-volunteer portion of Phase 1 had already been completed under Actio, and the program has received rare pediatric disease, orphan drug, and fast-track designations, according to Fierce Biotech [Fierce Biotech, October 2026] [Pharmacally]. If Setara can translate those ingredients into clean patient data, the company could move from an asset transfer story to a franchise story.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Rare-disease beachhead | STAR-0871 shows encouraging signal in CMT2C and becomes the anchor product around which Setara builds a focused neuromuscular franchise | Initiation and early readout from the planned Phase 1b CMT2C study in 2027 [BioPharma Dive, October 2026] [Fierce Biotech, October 2026] | The asset is already through healthy-volunteer Phase 1 work, and the program carries orphan, fast-track, and rare pediatric disease designations that can support an efficient development path [Fierce Biotech, October 2026] |
| One mechanism, two markets | The company uses the same TRPV4 program to bridge from a rare genetically defined indication into a broader urology market, improving the commercial ceiling of the lead asset | Clear clinical rationale and continued development in overactive bladder alongside rare disease [Business Wire, October 2026] [Pharmacally] | Public materials already identify both CMT2C and overactive bladder as target indications, which suggests management is pursuing an indication-expansion logic from the outset [Business Wire, October 2026] [BioSpace, October 2026] |
| Spinout-to-platform | A successful lead program gives Setara financing and strategic room to advance earlier-stage programs in rare diseases, epilepsy, and migraine, turning a single-asset launch into a multi-program genetics company | Positive early clinical data plus follow-on capital from the existing syndicate or strategic partners [Business Wire, October 2026] [Axios Pro, October 2026] | The company launched with a large Series A and stated plans for additional earlier-stage programs beyond STAR-0871, indicating investor appetite for a broader build if the first program works [Business Wire, October 2026] [BioPharma Dive, October 2026] |
The compounding mechanism is straightforward even if it is not yet proven. One clinical win would validate more than a single molecule. It would validate Setara's claim that human genetics can be used to identify disease-driving targets in severe rare disease, which in turn should make it easier to recruit patients, attract specialist investigators, raise follow-on capital, and extend into adjacent channelopathies or neurologic indications that rely on similar translational logic [Business Wire, October 2026] [BioPharma Dive, October 2026]. In practice, that is how rare-disease biotech franchises are built: a credible first asset lowers the cost of capital and the burden of belief for the second and third assets.
There is also a structural advantage in the company's origin. Setara emerged from the residual pipeline of Actio after Jazz's acquisition, and Jazz appears both as the acquirer of the parent company and as an investor in the new entity [Business Wire, October 2026] [Fierce Biotech, October 2026]. That does not guarantee downstream partnering or an exit, but it does mean Setara begins with an unusually informed cap table for a launch-stage biotech. If STAR-0871 produces differentiated patient data, the company would be selling investors and potential partners a de-risked biological thesis rather than a first-principles discovery story.
The size of the win is best framed through the only credible public transaction anchor in the source set. Jazz acquired Actio Biosciences for up to $820 million in a deal centered on a different lead program, while Setara retained the remaining pipeline and launched separately with $90 million to advance those assets [Fierce Biotech, October 2026] [RamaOnHealthcare]. That does not imply a valuation range for Setara today, and it should not be read that way. It does show that strategic buyers will pay substantial sums for genetically informed neurology assets when the clinical and mechanistic case is strong. If Setara were to deliver compelling proof-of-concept in CMT2C and establish a credible path in a second indication, a strategic outcome in the high hundreds of millions of dollars is conceivable (scenario, not a forecast), especially if the company has by then converted STAR-0871 from a single inherited asset into the first validated node of a broader pipeline [Fierce Biotech, October 2026] [Business Wire, October 2026].
Partially corroborated -- This section relies on multiple named public sources for financing, spinout history, investor syndicate, indication targets, and development status, but several material product and pipeline details remain company-announced or reported by a single trade publication.
Sources
Open sources
[Business Wire, October 2026] Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications | https://www.businesswire.com/news/home/20261030022827/en/
[Fierce Biotech, October 2026] Jazz’s Actio buyout gives rise to Setara with $90M series A | https://www.fiercebiotech.com/biotech/setara-raises-90m-series-carrying-actio-torch-following-jazz-acquisition
[BioPharma Dive, October 2026] With Setara, the team behind Actio opens its second act | https://www.biopharmadive.com/news/setara-actio-charcot-marie-tooth-ion-channel-drugs/873227/
[Setara Biosciences] Home - Setara Biosciences | https://www.setarabiosciences.com/
[Pharmacally] Setara Raises $90M to Advance STAR-0871 for CMT2C and Overactive Bladder | https://pharmacally.com/setara-biosciences-90-million-series-a-star-0871-cmt2c/
[Axios Pro, October 2026] Setara Biosciences raises $90M Series A | https://www.axios.com/pro/biotech-deals/2026/10/30/setara-biosciences-raises-90m
[Bloomberg Markets] David Goldstein, Actio Biosciences Inc: Profile and Biography - Bloomberg Markets | https://www.bloomberg.com/profile/person/25247210
[Reuters, April 2016] AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep | https://www.reuters.com/article/us-astrazeneca-genomics-idUSKCN0XI2Z1
[LinkedIn] David Breckenridge | https://www.linkedin.com/
[GenomeWeb, October 2026] Setara Lands $90M in Series A Financing | https://www.genomeweb.com/business-news/financial/financing/gnw-setara-series-a-90m-neuromuscular-20261030/
[allsci.com] Setara raises USD 90 million to advance rare disease pipeline following Actio spinout | https://allsci.com/news/trpv4-inhibitor-setara-raises-usd-90m-series-a/
[BioSpace, October 2026] New biotech Setara forms with $90m to take on Jazz’s bonus rare disease programs | https://www.biospace.com/business/new-biotech-setara-forms-with-90m-to-take-on-jazzs-bonus-rare-disease-programs
Articles about Setara Biosciences
- A $90 Million Spinout Takes on Charcot-Marie-Tooth Disease — The spinout from Jazz's Actio acquisition will use its Series A to fund a Phase 1b study for its lead program, STAR-0871, in 2027.